Breast IHC AI

New zero-click preprocessing automatically identifies invasive carcinoma and excludes DCIS, LCIS, and control tissue before ER, PR, HER2, and Ki67 quantification. Shown here is the HALO Breast IHC AI out put of a stained HER2 slide with AI overlay only in the regions of invasive cancer.

Indica Labs Advances Breast Cancer AI with Zero-Click Tissue Classification Prior to Biomarker Analysis

HALO AP, News, Press Releases / , , , , , , ,

Albuquerque, NM, July 28, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced new intelligent tissue classification capabilities for HALO Breast IHC AI, its AI-powered breast biomarker quantification suite, seamlessly deployed in HALO AP®. This enhanced new version introduces fully automated identification and exclusion of positive control tissue, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), and areas of benign tissue prior to biomarker analysis. This zero-click preprocessing and tissue classification workflow represents a critical step in ensuring accurate and reproducible AI outputs.

Indica Labs Advances Breast Cancer AI with Zero-Click Tissue Classification Prior to Biomarker Analysis Read More »

A lap top looking over the Sandia mountains in Albuquerque, NM; showcasing an IHC breast tissue image on the lap top screen with HER2 3+ stanning. Using AI and digital pathology for precision medicine, anytime anywhere.

AI and Digital Pathology in Personalized Medicine: The Past, Present, and Future of Breast Cancer Care

Blogs, Breast IHC AI, HALO AP, News / , , , , ,

AI-powered digital pathology is redefining modern cancer care by extending clinical-grade insights beyond the microscope and enabling standardized, pixel-level analysis to support scalable cancer diagnostics anytime, anywhere.

AI and Digital Pathology in Personalized Medicine: The Past, Present, and Future of Breast Cancer Care Read More »

Looking Back: Reviewing 2025 at Indica Labs

Blogs, Breast IHC AI, Cloud Services, CRC Macrodissect AI, HALO, HALO AI, HALO AI Apps, HALO AP, HALO AP Dx, HALO Clinical AI, HALO Link, Lung Macrodissect AI, News, Pharma Services, SlideQC BF / , , , , , , , , , ,

As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.

Looking Back: Reviewing 2025 at Indica Labs Read More »

The rapid global adoption of HALO AP® prompted immediate localization of the platform in Chinese, Danish, Dutch, American and British English, Finnish, French, German, Greek, Italian, Norwegian, Japanese, Portuguese, Russian, Spanish, Slovakian, and Swedish. Shown here are all 17 languages represented as each country's flags.

Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets

Breast IHC AI, HALO AP, HALO AP Dx, HALO Clinical AI, HALO Macrodissect Solutions, Lung Macrodissect AI, News, Press Releases / , , , , , , , ,

Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.

Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »

Indica Labs' HER2 low and ultralow UI

Low and Ultralow HER2 Expression in Breast Cancer is Now Detectable by Indica Labs’ Breast IHC AI

Breast IHC AI, HALO AP, HALO Clinical AI, News, Press Releases / , , , , , ,

Albuquerque, NM, April 30, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today an update to their Breast IHC AI suite, an image analysis tool used for the quantification of HER2, ER, PR, and Ki67 within AI-identified, tumor regions, of breast cancer tissue specimens. The HER2 algorithm will now include functionality for the detection of low and ultralow HER2 expression in breast cancer.

Low and Ultralow HER2 Expression in Breast Cancer is Now Detectable by Indica Labs’ Breast IHC AI Read More »

Free Demo
Free Demo
Scroll to Top